US-based Milestone Scientific’s (MLSS) subsidiary Milestone Medical has secured CE Mark to market and sell its epidural injection system the CompuFlo Epidural Computer Controlled Anesthesia System (CompuFlo Epidural Model 6000) in Europe.

The system is intended for verification of needle tip placement in the lumbar epidural space in patients aged 18 years and older.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will also be used for the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their health care provider.

Milestone Scientific chief executive officer Leonard Osser said: "CE approval is an important achievement and further validation of our technology as our subsidiary moves towards commercial sale of the epidural injection system.

"CE approval is an important achievement and further validation of our technology as our subsidiary moves towards commercial sale of the epidural injection system."

"Our subsidiary’s next steps involve securing strategic partners to distribute its products in Europe, as it has already done in the US. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago.

"Millions of patients that require epidural drug delivery and millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"Epidurals represent a multi-billion dollar global market and we believe our technology can transform these injections from an art to a science."

The injection technology is based on a patented dynamic pressure sensing system (DPS), which is used to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection.

The system uses computer controlled technology to offer real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact